Eurofins stock adds Toronto investor event as outlook softens
Published on 11/04/2026 at 18:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth update and investor event
- Eurofins reported 9M revenue of 5.614 billion euros, while organic growth improved sequentially through the third quarter.
- The company expects 2026 organic growth below its previous mid-single-digit objective but kept profitability and cash-flow goals unchanged.
- Investors and analysts are due to meet Eurofins in Toronto on November 11, 2026.
Eurofins Scientific has added an investor event to the near-term agenda as the laboratory-testing group balances improving quarterly momentum with a softer 2026 organic-growth outlook. Eurofins will host investors and analysts at its campus in Toronto, Canada, on November 11, according to its investor-relations page.
What has changed since the last report
The Toronto event is the latest confirmed investor date after the group's nine-month trading update, published on October 21 before the opening of Euronext Paris. The update showed reported revenue of 5.614 billion euros for the first nine months of 2026, up 3.7 percent from the prior-year period.
Organic growth improved from 2.5 percent in the first quarter to 3.0 percent in the second and 3.5 percent in the third. BioPharma Product Testing delivered mid-single-digit growth, while Discovery & Genomics returned to positive growth. The stronger quarterly sequence has not restored the previous full-year objective.
Guidance remains the central issue
Eurofins expects full-year 2026 organic growth to remain below its previous mid-single-digit objective. Management cited slower-than-normal market conditions and clinical programs that are not expected to restart during 2026. Acquisition revenue is expected to exceed the previous annualized objective of 250 million euros, providing a counterweight to weaker underlying demand.
The group kept its 2026 profitability and cash-flow objectives unchanged. Adjusted EBITDA margin is expected to improve from 22.5 percent in 2025, while the 2027 objective remains 24 percent. Investors will therefore focus on whether productivity projects, the hub-and-spoke laboratory network and acquisitions can support margins while organic demand recovers.
Quote and market context
Eurofins stock traded at 88.47 euros on Lang & Schwarz at 18:07 CET on Wednesday, November 4, 2026. The real-time quote of Eurofins stock is available here.
Eurofins Scientific SE at a glance
- Company: Eurofins Scientific SE
- ISIN: FR0014000MR3
- Latest quote: 88.47 euros on Lang & Schwarz, November 4, 2026, 18:07 CET
- Industry: Medical diagnostics and research
- Sector: Healthcare
The CAC 40 provides the French market backdrop for Eurofins investors.
More news and analyses on Eurofins stock cover the company's growth outlook, acquisitions and operating performance.
